核医学 (NM) の世界市場：成長率、動向、予測
Nuclear Medicine Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||319327|
|出版日||ページ情報||英文 112 Pages
|核医学 (NM) の世界市場：成長率、動向、予測 Nuclear Medicine Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年03月01日||ページ情報: 英文 112 Pages||
当レポートでは、世界の核医学 (NM) 市場について調査分析し、市場概要、市場力学、市場区分、競合情勢、主要企業などについて、体系的な情報を提供しています。
Nuclear medicine falls under the field of molecular imaging, which involves the use of a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by special types of cameras attached to the computer, which in turn, provide very precise pictures of the area of the body examined.
Cardiology Application is Expected to Experience Strong Growth in the Market
The application segment is further sub-segmented into cardiology, neurology, oncology, and other applications. The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases (CVD) over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died, due to CVDs.
The diagnostics segment is further segmented into SPECT and PET. PET imaging radioisotopes have many applications in clinical neurology, which involves movement disorders, epilepsy, brain tumors, dementia, stroke, and neuronal plasticity. Future applications include early diagnosis of brain metastases, Parkinson syndromes, and neurodegenerative disorders, such as Alzheimer's disease. The market for radioisotopes is expected to be larger in the developing countries because of the increasing awareness among people about radioisotopes, increasing the incidence of chronic diseases, like cancer, and increasing population.
North America is Expected to Dominate the Nuclear Medicine Market
North America is the dominant market for nuclear medicine. Within North America, the United States is the largest consumer market for radioisotopes, and Canada is the largest producer of Tc-99m. The United States was the largest contributor to the North American region, in terms of revenue, and it is expected to retain its dominance, owing to the higher procedural volume and increasing adoption of nuclear medicine for various therapeutic applications.
Asia-Pacific is expected to witness healthy CAGR during the forecast period. A rise in demand for nuclear medicines in emerging countries, such as India and China, is due to the rise in disposable income, improving healthcare standards, and favorable reforms in foreign policies.
There is high competition among the players of the global nuclear medicine market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. For instance, April 2017, IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium, a world-class provider in nuclear imaging. Various developments have recently been taking place in the market, such as and in May 2018, Curium enhanced its position in the French PET market with the acquisition of Cyclopharma's French commercial and manufacturing operations.